Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fsd Pharma Inc Cl B
(NQ:
HUGE
)
0.1522
+0.0141 (+10.21%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Jul 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,703,600
Open
0.1400
Bid (Size)
0.1452 (23)
Ask (Size)
0.1530 (50)
Prev. Close
0.1381
Today's Range
0.1356 - 0.1587
52wk Range
0.1300 - 1.680
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Amends Original Material Change Report, Files Amended and Restated MCR
July 05, 2024
Via
Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Retains Digital Marketing Platform to Increase Market Awareness
July 01, 2024
Via
Investor Brand Network
Performance
YTD
-83.09%
-83.09%
1 Month
-17.37%
-17.37%
3 Month
-67.21%
-67.21%
6 Month
-82.42%
-82.42%
1 Year
-86.29%
-86.29%
More News
Read More
FSD Pharma provides Corporate Update
June 28, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Awarded Final Judgment, Confirmation of $3M-Plus Arbitration Award
June 28, 2024
Via
Investor Brand Network
HUGE Stock Earnings: FSD Pharma Reported Results for Q1 2024
May 20, 2024
Via
InvestorPlace
FSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.
June 28, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
June 27, 2024
Via
Investor Brand Network
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Notes ‘Important Step’ as Phase 1 Lucid-21-302 Trial Receives HREC Approval
June 27, 2024
Via
Investor Brand Network
FSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia
June 27, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA:0K9A) Signs Option Agreement with USC to Exclusively Evaluate Novel Technology for Commercialization
June 13, 2024
Via
Investor Brand Network
FSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business Applications
June 13, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces IRB Approval for Acute Alcohol Intoxication Study
June 04, 2024
Via
Investor Brand Network
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
June 04, 2024
Via
ACCESSWIRE
InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Wins Petition, Awards for Damages and Fees
May 31, 2024
Via
Investor Brand Network
FSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus Interest
May 31, 2024
Via
ACCESSWIRE
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
May 29, 2024
Via
Investor Brand Network
MiningNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
May 29, 2024
Via
Investor Brand Network
BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency
May 28, 2024
Via
Investor Brand Network
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication
May 28, 2024
Via
ACCESSWIRE
FSD Pharma Provides Corporate Update
May 24, 2024
Via
ACCESSWIRE
FSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)
May 16, 2024
Via
ACCESSWIRE
TechMediaBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Marks Important Step in Advancing Lucid-21-302
May 07, 2024
Via
Investor Brand Network
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
May 07, 2024
Via
ACCESSWIRE
BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Agreement to Conduct Clinical Trial to Assess Safety, Efficacy of unbuzzd(TM)
April 30, 2024
Via
Investor Brand Network
FSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol Intoxication
April 30, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.